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Summary
Background: Porphyrin metabolism disorders, known as
porphyria, represent inherited or acquired diseases. The
development of porphyria due to light sensibility occurs
especially with exposure to wavelengths in the range of
300–700 nm. Skin reactions and neurovisceral dysfunc-
tions are known side effects of ionizing irradiation. It can
be postulated that during or after ionizing irradiation
treatment of patients affected with tumor and porphyria,
severe side effects might appear, in contrast to patients
without porphyria. This paper describes the treatment of
2 patients affected with tumor and concomitant por-
phyria. Patients: One female patient suffering from inter-
mittent porphyria and breast cancer and one male patient
suffering from porphyria cutanea tarda and bladder cancer
were treated with ionizing irradiation (electrons and
photons). No abnormalities nor any severe general or
local side effects could be observed. Conclusion: Radia-
tion therapy is not a ‘stimulating’ factor in activating
porphyria symptoms.
Schlüsselwörter
Porphyrin · Ionisierende Strahlung · Mammakarzinom · 
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Zusammenfassung
Hintergrund: Angeborene und erworbene Störungen des
Porphyrinstoffwechsels sind als «Porphyria» bekannt 
und durch eine Empfindlichkeit gegenüber Licht mit
Wellenlängen zwischen 300 und 700 nm gekennzeichnet.
Bekannte Nebenwirkungen der Strahlentherapie sind
Hautreaktionen sowie neuroviszerale Dysfunktionen. Man
kann annehmen, dass es bei der Behandlung von Patien-
ten mit Porphyrie und Tumorkrankheiten zum Auftreten
schwerer Nebenwirkungen kommen wird, im Gegensatz
zu Patienten ohne Porphyrie. Über die aktuellen Behand-
lungsergebnisse zweier Patienten mit malignenTumoren
bei gleichzeitig bestehender Porphyrie wird berichtet.
Patienten: Eine Patientin mit akuter intermittierender
Porphyrie und Mammakarzinom sowie ein Patient mit
Porphyria cutanea tarda und Blasenkarzinom wurden mit
ionisierender Strahlung (Elektronen und Photonen)
behandelt. Es wurden weder außergewöhnliche Reak-
tionen noch stark ausgeprägte allgemeine oder lokale
Nebenwirkungen verzeichnet. Schlussfolgerung: Die
Strahlentherapie wirkt nicht als «Auslöser» für die Akti-
vierung einer bestehenden Porphyrie.
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Introduction
Porphyria is characterized by porphyrin accumulation. Por-
phyrias are inherited or acquired disorders of specific enzymes
in the heme biosynthetic pathway. These kinds of disorders are
classified as either hepatic or erythropoietic, depending on the
primary site of the overproduction and accumulation of the
porphyrin precursor or porphyrin [1]. Porphyrins are the one
important class of photosensitizers definitely synthesized
internally by the body. In ‘cutaneous porphyria’ the presence of
abnormal quantities of porphyrins in the skin results in acute
or chronic photosensitivity. Today it is known that human por-
phyria is due to specific inherited defects, each representing a
partial deficiency of one of the seven enzymes beyond ALA
synthesis, and they are characterized by typical excretion
patterns. Biochemical studies of the different porphyrins and
precursors in urine, blood, and stool will allow the accurate
diagnosis of each porphyria. The current classification defines
the acute and non-acute types of porphyria, based on the main
clinical presentation, which also considers their possible skin
photosensitivity [2]. In 6–8 types of porphyria, the primary
clinical manifestation is represented by skin photosensitization.
Two types of porphyrias (acute intermittent porphyria and
plumboporphyria) are non-cutaneous (there is no skin photo-
sensitivity), but are stated with other clinical manifestations
such as nausea, vomiting, abdominal pain and anxiety [2].
Porphyrin disorders other than porphyria may be found in a
number of other diseases, particularly anemia and hepatobili-
ary disorders or in disorders caused by drugs or chemicals, either
because the biosynthesis of heme is impaired or because the
mechanisms of porphyrin excretion are abnormal [1, 2]. Ac-
quired porphyrin disorders may be found in anemia, in hepa-
tobiliary disorders, benign and malignant hepatic tumors, in
intoxication or as paraneoplastic syndrome [3]. They often
exhibit skin photosensibility [3].
The activation of the porphyrins is by means of contact with
light, especially of wavelengths between 350 and 700 nm.
Ionizing radiation is effected by electromagnetic waves be-
tween 1 pm up to few nanometers. Ionizing irradiation is
appreciated in healing, as palliative and also as adjuvant
therapy. Side effects such as various skin reactions, e.g., skin
inflammation, edema, ulcer, and neurovisceral dysfunction are
well known.
Because of the skin sensitivity with porphyria, and because of
the possible occurrence of side effects such as skin reactions or
neurovisceral dysfunction after ionizing irradiation, it can be
postulated that patients affected with tumor and porphyria
tend to have more severe side effects than patients without
porphyria.
Patients and Methods
Two patients, a 48-year-old female and a 70-year-old male, have been
examined. Since 1991, the woman suffered from intermittent porphyria
subclassified as acute intermittent porphyria without significant skin mani-
festation. Since 1996, she also suffered from the classical signs of this kind
of porphyria showing especially neurological manifestations with motoric
polyneuropathia, abdominal pain, and kidney insufficiency. In March 1996,
cancer in the left breast was diagnosed (pT2pN0pM0). After mastectomy
no other adjuvant treatment was adopted, because hormone therapy 
such as Tamoxifen treatment can stimulate acute hepatic porphyria. In
November 1996, a recurrence surgery was performed on the left chest wall
without complete microscopic resection (R1 resection). From January 1997
to March 1997 we proceeded with a locoregional radiation treatment 
(50 Gy + 10 Gy boost) using photons and electrons. In 1998 the patient
returned to our department because of cerebral and mediastinal metas-
tases, which were treated with a total fractionated treatment dose of 
46 and 50 Gy, respectively. The patient died from metastases 4 months
later. During the irradiation treatment the patient had dialysis three times
per week because of kidney insufficiency. Coproporphyrin and uropor-
phyrin I and III in plasma were controlled before and after dialysis.
The second patient (male) suffered from porphyria cutanea tarda since
1990. In 1993, bladder cancer surgery with construction of an ileo-neo-
bladder was performed. In 1997, recurrence surgery became necessary with
construction of a preternatural anus. After the operation the patient was
treated with the linear accelerator using photons to a total fractionated
dose of 45 Gy and 9 Gy boost. The uroporphyrin level was measured
before and after irradiation in urine specimens. Both patients were con-
trolled clinically daily during the irradiation course. Clinical follow-up was
performed in the following 6 weeks and then every 3 months after treat-
ment. The monitoring consisted in skin control of the irradiation field,
tumor screening (laboratory, computed tomography, and urologic evalua-
tion of general status).
Results
The 2 patients did not show any severe skin side effects such as
inflammation or ulcers. The manifested acute side effects
remained in the normal range for patients treated with ionizing
irradiation.The patient with breast cancer showed only a slight
erythema in the boost field and no other acute, subacute or
chronic side effects by irradiation within the follow-up period
of 16 months after the first irradiation.The patient with bladder
cancer developed a light skin erythema in the anal region as
well as diarrhea at the end ot the irradiation period. The fol-
lowing controls did not show subacute or chronic side effects
resulting from irradiation within the follow-up period of 
24 months. The control before, during and at the end of irra-
diation of coproporphyrin and uroporphyrin I and III in the
plasma of the patient with acute intermittent porphyria
showed the following levels: coproporphyrin 0.3–0.4 g/dl (ref.
0–0.2 g/dl), uroporphyrin I 11–17 g/dl, uroporphyrin III
6.3–10.8 g/dl (ref. 0–0.2 g/dl), with a higher level before the
dialysis and a relative low level immediately after the dialysis.
A fractionated 24-hour urine specimen collected from the 2nd
patient before and at the end of the irradiation showed a
markedly elevated uroporphyrin level of 735 g / total volume
(ref.: 3–25 g / total volume), with only slight differences of
values before and after treatment.
Discussion
A variety of changes in normal tissues are induced by ionizing
irradiation, depending on the total dose, the fractionation
schedule (day and time), and the tissue volume to be treated
[4]. After the application of therapeutic doses of ionizing irra-
diation, cell death occurs at the time of mitosis [5]. The time to
develop tissue injury critically depends on the turnover time
and differentiation kinetics of the involved tissue. The time
dependency of this process is reflected by using the terms
‘acute’, ‘subacute’, and ‘late’ effects. These terms are used to
describe the response of normal tissue to ionizing radiation [4].
The accumulation of porphyrins yields a high skin sensitivity
to light, especially for wavelengths between 300 and 700 nm
[1]. Neuropathy and neurovisceral dysfunction are character-
istic in case of acute intermittent porphyria. This light sensi-
tivity is the main reason for symptoms such as red skin,
edema, and ulcer. These symptoms also occur after irradiation
treatments, too. Therefore, it is to be expected that patients
affected with porphyria can have severe skin side effects in
comparison to patients without porphyria after ionizing irra-
diation treatments.
Furthermore, there may be a connection between porphyria
and tumor. An abnormality of heme synthesis linked to
carcinogenesis initiation which increases the subsequent
mutation rate in the affected clone or the increase of intra-
cellular ROS (reactive oxygen species) during porphyria is an
important source of mutagenesis [2, 6]. The patient with
bladder cancer was operated 4 months after irradiation due
to hepatocellular tumor.
The scarce literature regarding the treatment of tumor patients
with concomitant porphyria by irradiation therapy showed no
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evidence of severe side effects [7, 8]. The information includes
4 patients with porphyria cutanea tarda [7] and 1 patient with
variegata porphyria [8].
The wavelength of the ionizing radiation applied during irra-
diation treatment of our patients was ca. 1 pm for electrons and
ca. 3 pm for photons, in other words, far beyond the activation
wavelength of porphyrins (350–700 nm).
Based on the scarce literature and our 2 case reports, we can
presume that for patients suffering from tumor with conco-
mitant porphyria who are treated with radiation therapy, the
probability of side effects will not differ from that of patients
with only tumor.
Before treatment, the irradiated skin area needs to be examined
carefully to avoid severe skin damage in already existing lesions.
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